Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir for mild to moderate COVID-19
IRCT20201005048936N1Phase 3Completed
- Sponsor
- Dr. Abidi Pharmaceuticals
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of favipiravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Dr. Abidi Pharmaceuticals. Primary endpoints: Proportion of patients with negative PCR test, Time to symptom recovery and 1 more. Started Oct 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20201005048936N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201005048936N1.